Press Releases

 
Press Releases
Date Title and Summary View
May 7, 2013 SALT LAKE CITY, May 7, 2013 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced results for its third fiscal quarter and nine months ended March 31, 2013. Revenue for the third fiscal quarter increased 21 percent over the same period in the prior year to $156.5 million. Third fiscal quarter earnings per diluted share were $0.46,...
May 2, 2013 SALT LAKE CITY, May 2, 2013 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that its Analyst and Investor Day for research analysts and institutional investors will take place on Thursday, May 9, 2013 at 9:00 a.m. EST in New York City.  Peter D. Meldrum, president and chief executive officer of Myriad, will host the event th...
May 2, 2013 SALT LAKE CITY, May 2, 2013 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today highlighted new clinical data on the PROLARIS 46-gene cell cycle progression (CCP) signature in patients with prostate cancer that will be presented at this year's American Urological Association (AUA) in San Diego. "We have realized for some time that...
Apr 18, 2013 SALT LAKE CITY, April 18, 2013 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that it will issue financial results for the third fiscal quarter 2013 following the close of market on Tuesday, May 7, 2013. The Company will also host a conference call on Tuesday, May 7, 2013 at 4:30 P.M. Eastern to review the financial...
Apr 17, 2013 SALT LAKE CITY and LEXINGTON, Mass., April 17, 2013 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) and RainDance Technologies, Inc. today announced that they have entered into a commercial agreement whereby Myriad will adopt RainDance's ThunderStorm™ Target Enrichment System for Myriad's next-generation sequencing based Hereditary Ca...
Mar 26, 2013 SALT LAKE CITY, March 26, 2013 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that it has signed an agreement with PharmaMar, a leader in the development of marine-derived drugs. Under the terms of the agreement, Myriad will conduct homologous recombination deficiency (HRD) testing on patients enrolled in PharmaMar's Phase ...
Mar 6, 2013 SALT LAKE CITY, March 6, 2013 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that three federal agencies including the U.S. Department of Health and Human Services, the U.S. Department of Labor, and the U.S. Department of the Treasury have issued a set of FAQs clarifying BRCA testing as a preventive service under the provis...
Mar 5, 2013 SALT LAKE CITY, March 5, 2013 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that a study published in the Journal of Clinical Oncology demonstrated that its Prolaris test, which analyzes the expression level of 46 cell cycle progression genes, accurately predicted the elevated risk for prostate cancer recurrence in 413 men...
Mar 1, 2013 SALT LAKE CITY, March 1, 2013 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that Noridian Administrative Services LLC ("Noridian"), Medicare administrative contractor for Jurisdiction F which includes Utah, has priced the new molecular pathology codes for calendar year 2013. Since all of Myriad's tests reimbursed by Medica...
Feb 5, 2013 SALT LAKE CITY, Feb. 5, 2013 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced results for its second fiscal quarter ended December 31, 2012. Revenue for the second fiscal quarter increased 21 percent over the same period in the prior year to $149.1 million.  Second fiscal quarter earnings per diluted share were $0.42, an incr...
Page: FirstPrevious ...
9
... NextLast
= add release to Briefcase